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Abstract 
Metamizole is an analgesic and antipyretic, but can cause neutropenia and 
agranulocytosis. We investigated the toxicity of the metabolites N-methyl-4-
aminoantipyrine (MAA), 4-aminoantipyrine (AA), N-formyl-4-aminoantipyrine (FAA) 
and N-acetyl-4-aminoantipyrine (AAA) on neutrophil granulocytes and on HL60 cells 
(granulocyte precursor cell line). MAA, FAA, AA, and AAA (up to 100 µM) alone were 
not toxic for HL60 cells or granulocytes. In the presence of the myeloperoxidase 
substrate H2O2, MAA reduced cytotoxicity for HL60 cells at low (<50 µM), but 
increased cytotoxicity at 100 µM H2O2. Neutrophil granulocytes were resistant to 
H2O2 and MAA. Fe
2+ and Fe3+ were not toxic to HL60 cells, irrespective of the 
presence of H2O2 and MAA. Similarly, MAA did not increase the toxicity of lactoferrin, 
hemoglobin or methemoglobin for HL60 cells. Hemin (hemoglobin degradation 
product containing a porphyrin ring and Fe3+) was toxic on HL60 cells and cytotoxicity 
was increased by MAA. EDTA, N-acetylcystein and glutathione prevented the toxicity 
of hemin and hemin/MAA. The absorption spectrum of hemin changed concentration-
dependently after addition of MAA, suggesting an interaction between Fe3+ and MAA. 
NMR revealed the formation of a stable MAA reaction product with a reaction 
pathway involving the formation of an electrophilic intermediate. In conclusion, MAA, 
the principle metabolite of metamizole, increased cytotoxicity of hemin by a reaction 
involving the formation of an electrophilic metabolite. Accordingly, cytotoxicity of 
MAA/hemin could be prevented by the iron chelator EDTA and by the electron donors 
NAC and glutathione. Situations with increased production of hemin may represent a 
risk factor for metamizole-associated granulocytopenia. 
 
Key words: metamizole, N-methyl-4-aminoantipyrine, agranulocytosis, HL60 cells, 
hemin, iron  
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1. Introduction 
Metamizole is a non-opioid analgesic, antipyretic, and spasmolytic prodrug, which is 
widely used in certain countries due to its good efficacy and low gastrointestinal 
toxicity (1, 2). It is rapidly converted non-enzymatically to the active drug N-methyl-4-
aminoantipyrine (MAA) in the gut and in the mesenteric and portal circulation (Fig. 1). 
MAA has a good oral bioavailability and is converted enzymatically to the 4-
aminoantipyrine (AA) which is also physiologically active (3). The majority of AA is 
acetylated to N-acetyl-4-aminoantipyrine (AAA) and a smaller part is formylated to N-
formyl-4-aminoantipyrine (FAA) (4-6). Although metamizole has a favourable safety 
profile overall, susceptible patients may experience neutropenia or agranulocytosis, a 
severe and potentially fatal decrease of circulating neutrophil granulocytes (1, 7). The 
four major metabolites MAA, AA, AAA and FAA reach sufficiently high plasma (and 
presumably also bone marrow) concentrations to potentially be hematotoxic (8). The 
mechanisms underlying metamizole-induced neutropenia are poorly understood, and 
there are no effective strategies to predict in whom neutropenia is likely to occur, nor 
to prevent this life-threatening adverse drug reaction (9, 10). Bone marrow biopsies 
of affected patients showed a stop at the myelocyte stage in granulocyte maturation 
(11), indicating that the toxicity of metamizole affects the bone marrow and not 
peripheral granulocytes. An HLA-linked toxicity has been proposed in one study, 
suggesting an immunological mechanism (12). On the other hand, the absence of 
immunological features in affected patients and the onset within a few days after start 
of therapy in some previously unexposed patients are compatible with direct 
metabolic toxicity on bone marrow granulocyte precursors. 
Uetrecht et al. have shown that aminopyrine (N,N-dimethyl-4-aminoantipyrine), which 
is structurally closely related to MAA, can form reactive metabolites after oxidation by 
hypochlorite (13). Hypochlorite can be produced by myeloperoxidase, a heme-
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containing enzyme detectable in granulocyte maturation starting from promyelocytes, 
which are direct myelocyte precursors (14). Myeloperoxidase could therefore be 
involved in myelotoxicity associated with MAA. Myeloperoxidase is also present in 
circulating neutrophil granulocytes and in HL60 cells (15, 16), a human promyeloid 
cell line. The main function of myeloperoxidase is to destroy phagocytosed 
microorganisms by generating reactive intermediates within the phagosome (17, 18). 
The generation of reactive intermediates needs the presence of hydrogen peroxide 
(H2O2) and an anion such as chloride. H2O2 arises mainly from the respiratory burst 
produced by phagocyte NADPH oxidase (19). In the presence of H2O2, 
myeloperoxidase catalyzes the formation of reactive intermediates such as 
hypochlorous acid (HOCl), which can destroy phagocytosed microorganisms (20). 
Importantly, H2O2 is also a substrate for the Fenton reaction, which is dependent on 
Fe2+ and produces reactive hydroxyl radicals (21, 22). Since iron in the form of free 
iron (mainly Fe3+), ferritin (Fe3+) or complexed in heme (as Fe3+ or Fe2+) is abundant 
in bone marrow (23), an iron-mediated mechanism is a possibility for explaining the 
bone marrow toxicity of MAA. In favour of an iron-associated mechanism, Pierre et al. 
have shown that MAA and AA (but not FAA and AAA) react with heme-bound Fe3+ 
(24). 
In the current study, we investigated the possibility of direct (non-immunological) 
toxicity of metamizole and its metabolites (MAA, FAA, AA, and AAA) on circulating 
neutrophil granulocytes and on the human granulocyte precursor cell line HL60. For 
that, we investigated the possible involvement of myeloperoxidase, the Fenton 
reaction and of heme-bound iron in the cytotoxicity of MAA. The studies show that 
MAA reacts with Fe3+ in hemin, leading to the formation of electrophilic MAA 
metabolites that are cytotoxic. 
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2. Materials and Methods 
2.1. Chemicals and cell culture reagents 
We purchased metamizole, N-methyl-4-aminoantipyrine, N-formyl-4-aminoantipyrine, 
4-aminoantipyrine, and N-acetyl-4-aminoantipyrine, natrium chloride (NaCl), Tris-HCl, 
Fe(NO3)3, nitrilotriacetic acid (NTA), doxycycline, lactoferrin, iron chloride (Fe
3+), iron 
sulfate (Fe2+), sodium hydroxide (NaOH), hemoglobin, methemoglobin,hemin, 
glutathione (GSH), N-acetyl-cysteine (NAC), and ethylenediaminetetraacetic acid 
(EDTA) from Sigma–Aldrich (Buchs, Switzerland). We obtained RPMI 1640 medium, 
fetal bovine serum (FBS), and phosphate buffered saline (PBS) from GIBCO 
(Lucerne, Switzerland), dextran 500 from Roth AG (Arlesheim, Switzerland), Ficoll-
Paque from GE Healthcare (Glattbrugg, Switzerland) and BD Pharm Lyse lysing 
buffer as well as the 96-well cell culture plates from BD Biosciences (Franklin Lakes, 
NJ, USA).  
 
2.2. Promyelocytic HL60 cells 
We maintained HL60 cells (CCL-240, lot number 7703261, ATCC, Wesel, Germany) 
in RPMI medium supplemented with 10% FBS at 37°C in a humidified atmosphere 
containing 5% CO2. For all subsequent described assays, HL60 cells from passages 
11 to 25 were used. 
 
2.3. Mature neutrophil granulocytes 
We isolated the neutrophil granulocytes freshly from human whole blood obtained 
from the local blood donation center Basel (Switzerland). Since the donors remained 
anonymous, the study did not require approval from the local Ethics Committee. We 
isolated the neutrophils from the blood by a modification of the method described by 
Klebanoff et al. (25). Briefly, we diluted 20 mL blood with 25 mL phosphate-buffered 
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saline (PBS), carefully layered it over 15 mL Ficoll-Paque and centrifuged it at 200 g 
for 20 min. We discarded the supernatant and mixed the pellet with 4% dextran in 
0.9% NaCl solution and allowed the erythrocytes to settle for 30 min. We washed the 
supernatant layer with PBS and lysed the remaining erythrocytes with BD Pharm 
Lyse lysing buffer. Subsequently, we washed the cells twice with PBS and 
resuspended them in RPMI medium containing 10% fetal bovine serum (FBS). 
Viability was assessed by using trypan blue analysis and always exceeded >90%. 
We stained some samples with CD66b antibody (BioLegend, San Diego, CA, USA) 
and confirmed by flow cytometry analysis >92% content of neutrophil granulocytes. 
 
2.4. Effect of metamizole and metamizole metabolites on plasma membrane 
integrity 
For the experiments, we seeded 2x105 HL60 cells or 1x106 freshly isolated 
neutrophils in 1 mL RPMI containing 10% FBS in 2 mL Eppendorf tubes. The stock 
solutions of test compounds (metamizole, MAA, FAA, AA, and AAA) were prepared 
in DMSO (Sigma–Aldrich, Buchs, Switzerland). We added the test compounds to the 
cell-suspension at a concentration of 1-100 µM for metamizole, FAA, AA, AAA and 1-
200 µM for MAA. We chose these concentrations based on available 
pharmacokinetic data in humans (4). Subsequently, we added 50 µL of each 
suspension-mixture in triplicate to a 96-well plate and incubated the plate for 24 and 
48 hours at 37 °C, 5% CO2. The DMSO concentration did not exceed 0.1% in all 
incubations, including control incubations, as this DMSO concentration is not 
cytotoxic (26). We used Triton X (Sigma–Aldrich, Buchs, Switzerland) at a final 
concentration of 0.1% as a positive control for plasma membrane toxicity. We 
performed all experiments in triplicate and repeated them at least three times using 
different cell isolations. 
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To assess a possible loss of plasma membrane integrity, reflected by the release of 
adenylate kinase, we used the firefly luciferase system (ToxiLight® BioAssay Kit, 
Lonza, Basel, Switzerland). After incubation for 24 and 48 hours in presence of test 
compounds, we added 50 µL assay buffer to 50 µL cell suspension from treated cells 
and measured luminescence after 5 min of incubation with a Tecan Infinite pro 200 
microplate reader (Tecan, Männedorf, Switzerland). 
 
2.5. Determination of the cellular ATP content after incubation with metamizole 
and metamizole metabolites 
We incubated HL60 cells and neutrophil granulocytes with test compounds as 
described before. To assess the ATP content, which reflects the cellular energy 
metabolism, we used the CellTiter-Glo® luminescent assay (Promega Corporation, 
Madison, USA). After incubation for 24 and 48 hours in presence of test compounds, 
we added 50 µL assay buffer to 50 µL cell suspension from treated cells and 
measured luminescence after 10 min incubation with a Tecan Infinite pro 200 
microplate reader (Tecan, Männedorf, Switzerland). 
 
2.6. Determination of apoptosis and necrosis 
To determine the percentage of dead cells (including necrotic cells and cells in late 
apoptosis), we used propidium iodide (PI) (Molecular probes, Oregon, USA), a red 
fluorescent dye incapable to permeate intact or early apoptotic cells, but able to stain 
permeable necrotic cells by binding to nucleic acid. After the incubation of HL60 cells 
with 100 µM MAA and co-incubation with different concentrations (10-100 µM) of 
H2O2 (Sigma–Aldrich, Buchs, Switzerland) for 24 hours, the cells were centrifuged at 
500 g for 5 minutes and washed with PBS before PI staining (Molecular probes, 
Oregon, USA) at a final concentration of 10 ug/mL. After 15 minutes incubation in the 
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dark, we analyzed the cells with a CytoFLEX flow cytometer (Beckmann Coulter, 
Indianapolis, USA) and assessed the data using FlowJo software 10.08 (Tree Star, 
Ashland, OR, USA). 
To determine the percentage of early apoptotic cells, we used Annexin V, a Ca2+-
dependent phospholipid-binding protein with a high affinity for phosphatidylserine 
(PS). PS is located on the inner cytoplasmic surface of intact cell membranes. In 
apoptotic cells, PS is translocated to the outer leaflet of the plasma membrane, 
where Annexin V binds to it. After the incubation of HL60 cells with 100 µM MAA and 
different concentrations (10-100 µM) of H2O2 for 24 hours, the cells were centrifuged 
at 500 g for 5 minutes and washed with PBS before Alexa Fluor 488® Annexin V 
staining (Molecular probes, Oregon, USA). After 15 minutes incubation in the dark, 
we analyzed the cells with a CytoFLEX flow cytometer (Beckmann Coulter, 
Indianapolis, USA) assessed the data using FlowJo software 10.08 (Tree Star, 
Ashland, OR, USA). 
 
2.7. Incubation of metamizole metabolites with H2O2 
We prepared 2 x 105 HL60 cell suspensions or 1 x 106 freshly isolated neutrophils 
and added 100 µM MAA as described above. To simulate the neutrophil oxidation 
system, we also used H2O2 in PBS pH 7.4 at final concentrations of 10-100 µM. One 
hundred µM was the only concentration of H2O2 in HL60 cells, where the addition of 
MAA increased the cytotoxicity. For neutrophil granulocytes, we therefore used only 
this concentration. For that, 106 freshly isolated neutrophils were co-incubated with 
100 µM H2O2 and MAA as described above. We then assessed membrane integrity 
and ATP content as described previously. 
 
2.8. Cytotoxicity of MAA in the presence of HOCl 
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We prepared 2 x 105 HL60 cells in 2 mL Eppendorf tubes and added 100 µM MAA as 
described above. We then immediately added 100 µM HOCl (Sigma–Aldrich, Buchs, 
Switzerland), which would be the highest reachable concentration when 100 µM 
hydrogen peroxide is converted to HOCl by myeloperoxidase. We incubated the cells 
and assessed membrane toxicity and ATP content as outlined before. 
 
2.9. Cytotoxicity of MAA in the presence of H2O2 and free iron 
We prepared 2x105 HL60 cells in 2 mL Eppendorf tubes and added 100 µM MAA as 
described above. Before adding 10 to 100 µM of H2O2, we pre-incubated the reaction 
solution with 50 µL of ferrous iron (FeSO4) at a final concentration of 12.5 µM. Then, 
we incubated the cells for 24 hours and assessed membrane toxicity, ATP content 
and percentage of apoptotic and necrotic cells as outlined previously. 
 
2.10. Preparation of apo- and hololactoferrin 
To obtain apolactoferrin, 4 mg/mL lactoferrin was dissolved in MilliQ water and 
dialyzed intensively against 0.1 M citric acid/citrate buffer (pH 3.0) containing 0.1 M 
NaCl for 24 hours using a dialysis membrane with a molecular weight cutoff of 10’000 
Da (Slide-A-Lyzer® Dialysis Cassette, Thermo Scientific, USA). Afterwards, we 
dialyzed the obtained apolactoferrin solution against MilliQ water for 24 hours. 
To obtain hololactoferrin, we dissolved 4 mg/mL lactoferrin in 10 mM Tris-HCl buffer 
(pH 7.2) containing 74 mM NaCl. We then added freshly prepared Fe nitrilotriacetic 
acid (NTA) solution consisting of 9.9 mM Fe(NO3)3 and 8.5 mM NTA in water and 
adjusted the pH to 7.0 with 5 M sodium bicarbonate solution. To achieve the highest 
possible iron saturation, we used an iron to lactoferrin molar ratio of 4:1 (27). 
To determine the iron saturation of the different lactoferrin varieties, we measured the 
absorption spectrophotometrically at 280 nm and 465 nm (28). We determined an 
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iron content of 15.5%, 63%, and 87% for apolactoferrin, lactoferrin, and 
hololactoferrin, respectively. 
 
2.11. Cytotoxicity of MAA in the presence of lactoferrin or different free iron 
compounds 
For the cytotoxicity assays we prepared 2 x 105 HL60 cells in 2 mL Eppendorf tubes 
and added 100 µM MAA as described above as well as 4 µg/mL lactoferrin, or apo- 
or hololactoferrin or 12.5 µM FeSO4 or FeCl3. Then, we incubated the cells for 24 
hours and assessed membrane toxicity and ATP content as outlined previously. 
 
2.12. Cytotoxicity of MAA in the presence of hemoglobin, methemoglobin or 
hemin 
We prepared 2 x 105 HL60 cells in 2 mL Eppendorf tubes and added 100 µM MAA 
and 500 µg/mL hemoglobin, methemoglobin or 12.5 µM hemin. Similarly, we 
prepared 1 x 106 neutrophil granulocytes in 2 mL Eppendorf tubes and added 100 
µM MAA and 12.5 and 25 µM hemin. Since hemin is not readily soluble in PBS, we 
first dissolved it in 10 mM NaOH as a 1 mM stock solution and then diluted it to the 
final concentration. We also added an equivalent concentration of NaOH to the 
vehicle control. Then, we incubated the cells and assessed membrane toxicity, ATP 
content and Annexin V/PI staining as outlined previously. 
To chelate the added iron of hemin, we added 100 µM EDTA (29) to the reaction 
solution 15 minutes before addition of hemin. Further, to scavenge possible radicals 
1 mM glutathione (GSH) or 1 mM N-acetylcysteine (NAC) (final concentrations) were 
added to the reaction solution in the same way as EDTA mentioned before. 
 
2.13. Activation of pro-apoptotic caspase-3/7 
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We prepared 2 x 105 HL60 cells in 2 mL Eppendorf tubes and added 100 µM MAA 
and 12.5 µM hemin as mentioned before. To assess the activity of caspase-3/7, 
which plays a key effector role in apoptosis, we used the Caspase-Glo® 3/7 
luminescent assay (Promega Corporation, Madison, USA). After incubation for 24 
hours in presence of the test compounds, we added 50 µL assay buffer to 50 µL cell 
suspension from treated cells and measured luminescence after 60 min of incubation 
with a Tecan Infinite pro 200 microplate reader (Tecan, Männedorf, Switzerland). 
 
2.14. Interaction of MAA with hemin 
We performed a spectrophotometric titration to assess whether MAA has an effect on 
hemin absorption. The chromophoric character of hemin makes it possible to follow a 
possible reaction via absorption spectroscopy. Absorption spectra were measured 
using a Varian-Cary 5000 spectrophotometer. Hemin disodium salt (0.35 mM) was 
dissolved in D2O and an absorption spectrum was recorded in the range 200 - 700 
nm. MAA was added to the solution in steps of 0.5 equivalents up to 4 equivalents. 
An absorption spectrum was recorded after each addition of MAA. 
 
2.15. NMR kinetic 
Hemin (0.5 mM) was dissolved in D2O in a 5 mL round-bottomed flask. After the 
addition of MAA (2 mM), the solution was heated to 37 °C. The flask was equipped 
with a septum containing a needle to guarantee diffusion of atmospheric oxygen. 
After defined time points, 1H and 13C NMR spectra were recorded at room 
temperature using a Bruker Advance III-500 NMR spectrometer. Stability of MAA in 
D2O was confirmed by NMR kinetic runs on a solution of MAA in D2O kept at 37 °C 
over the course of one week (data not shown). 
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2.16. Data analysis 
Data are presented as the mean ± SEM from at least three independent experiments. 
We measured each value in triplicate. We used GraphPad Prism software (GraphPad 
Software Inc., San Diego, CA, USA) for statistical analyses. Differences between 
many groups were tested by one-way ANOVA followed by Bonferroni’s multiple 
comparison test to localize significant results in the ANOVA. Differences within two 
groups were tested by an unpaired t-test. A p <0.05 was considered to be a 
significant difference. 
 
 
3. Results 
3.1. Plasma membrane toxicity and ATP depletion by metamizole and 
metamizole metabolites in HL60 cells and neutrophil granulocytes 
Freshly isolated human granulocytes and HL60 cells, a granulocyte precursor cell 
line expressing myeloperoxidase (15), were used as cell models for assessing 
plasma membrane toxicity of metamizole and metamizole metabolites. Metamizole 
(up to 100 μM), N-methyl-4-aminoantipyrine (MAA, up to 200 μM), 4-aminoantipyrine 
(AA), N-acetyl-4-aminoantipyrine (AAA) and N-formyl-4-aminoantipyrine (FAA) (all up 
to 100 μM) showed neither toxicity for HL60 cells (Fig. 2A and 2B), nor for freshly 
isolated human granulocytes after 24 hours incubation (Fig. 2C and 2D) or 48 hours 
incubation (data not shown). 
 
3.2. Possible role of MPO in MAA associated plasma membrane toxicity in 
HL60 cells 
Membrane toxicity of MAA and AA could be related to myeloperoxidase activity, 
which is expressed in HL60 cells (14, 15). In the presence of chloride and H2O2, 
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MPO can form hypochlorite, which is used by granulocytes for destroying bacteria 
(18, 20) and which could react with MAA or AA and form toxic metabolites (13). We 
therefore assessed the toxicity of MAA and AA in the presence of H2O2, the substrate 
of MPO, in the presence of chloride. 
As shown in Fig. 3A, 100 µM MAA did not impair membrane integrity of HL60 cells, 
whereas H2O2 showed a concentration-dependent toxicity, reaching significance at 
10 µM. Up to 25 µM H2O2, MAA significantly prevented the toxicity of H2O2, but at 
100 µM, MAA rendered H2O2 more toxic. The cellular ATP content dropped H2O2 
concentration-dependently to less than 10% of control values for 100 μM H2O2, 
whereas 100 µM MAA did not significantly reduce the cellular ATP content (Fig. 3B). 
MAA partially prevented the H2O2-associated drop in the cellular ATP content for all 
H2O2 concentrations investigated. The assessment of the apoptotic and necrotic cell 
fractions showed a H2O2 concentration-dependent increase predominantly in necrotic 
cells (Fig. 3C). The apoptotic cell fraction increased up to 25 μM H2O2, whereas at 
higher H2O2 concentrations only the necrotic fraction further increased. Similar to the 
findings for membrane toxicity, MAA was protective up to 25 μM H2O2 but increased 
the necrotic cell fraction at 100 μM H2O2. Similar results regarding membrane toxicity 
and cellular ATP content were found for the incubation of 100 μM AA with 100 μM 
H2O2, whereas FAA and AAA had no effect on H2O2 cytotoxicity (data not shown). 
Interestingly, freshly isolated neutrophils were much more resistant to the toxic 
effects of H2O2 and MAA (data not shown). H2O2 alone was not membrane-toxic and 
did not deplete the cellular ATP pool. Furthermore, the addition of MAA (up to 200 
μM) did not affect membrane toxicity or cellular ATP depletion in the presence of 
H2O2. 
In order to test directly the possibility that hypochlorite could mediate the toxicity of 
MAA or AA, we incubated HL60 cells with up to 200 µM MAA or AA in the presence 
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of 100 µM NaClO (data not shown). Under these conditions, we did not observe 
membrane toxicity or cellular ATP depletion, excluding a role of hypochlorite in MAA-
associated toxicity. 
We also performed experiments in the presence of the MPO inhibitor PF1335 (30), 
which did not change the effect of 100 µM H2O2 in the absence or presence of 100 
µM MAA on membrane integrity and ATP content of HL60 cells (results not shown). 
These results indicated that myeloperoxidase has no important role in the toxicity of 
MAA and AA. We therefore concentrated on a possible role of the Fenton reaction or 
other iron-related mechanisms for myelotoxicity of MAA and AA. Iron compounds are 
common in the human body and are known to be reactive and to be able to form 
cytotoxic metabolites from organic compounds (22). 
 
3.3. Cytotoxicity of MAA in the presence of different free iron compounds 
In a next step, we assessed the cytotoxicity of the iron compounds FeSO4 and FeCl3, 
which contain Fe2+ and Fe3+ respectively. These iron compounds provide free iron 
ions in aqueous solution and MAA may react with them to give cytotoxic metabolites. 
However, that neither the Fe2+ and Fe3+ ions were associated with membrane toxicity 
or decreased cellular ATP levels of HL60 cells in the presence of MAA (data not 
shown). 
Next, we investigated the possibility that MAA could increase cytotoxicity of the 
combination Fe2+ and H2O2. As shown in Fig. 4, cytotoxicity of H2O2 was not 
increased in the presence of Fe2+. Similar to incubations containing only H2O2 (shown 
in Fig. 3), the addition of MAA decreased membrane toxicity (up to 10 µM H2O2), ATP 
depletion and cytotoxicity in incubations containing Fe2+ and H2O2. 
 
3.4. Cytotoxicity of MAA in the presence of different forms of lactoferrin 
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Lactoferrin, a protein containing Fe3+, is found in secondary granules of neutrophils 
(31, 32) and, to a lower extent, in blood and plasma (33). During inflammation, the 
plasma lactoferrin concentration as well as the amount on the neutrophil surface 
increase due to neutrophil degranulation (31, 32). MAA and AA may react with 
lactoferrin and form cytotoxic metabolites. In order to test this hypothesis, we 
incubated HL60 cells and MAA with lactoferrins of different iron saturation and 
assessed membrane toxicity and ATP content of the cells. As shown in Fig. 4D and 
4E, none of the different lactoferrin forms was more cytotoxic (membrane damage 
and ATP content) when incubated with MAA. Lactoferrin itself slightly impaired 
membrane integrity, but had no effect on the cellular ATP content. Since we chose a 
2 to 3 fold higher lactoferrin concentration than the highest concentrations observed 
in human plasma (33), we considered it as unlikely that lactoferrin contributed to 
metamizole-induced neutropenia. This may be due to the fact that the iron in 
lactoferrin is well embedded and protected against environmental effects, making 
reactions with MAA and cytotoxic metabolite formation unlikely. 
 
3.5. Cytotoxicity of MAA in the presence of hemoglobin, methemoglobin or 
hemin 
Hemoglobin is another physiologically occurring compound containing iron. It is 
contained in erythrocyte precursors in bone marrow (in the vicinity of granulocyte 
precursors) and in mature erythrocytes in the blood. Both hemoglobin (containing 
Fe2+) and its oxidized form methemoglobin (containing Fe3+) represent an iron source 
that could possibly react with MAA to form cytotoxic intermediates. Hemoglobin 
consists of four subunits, each with a heme group containing an iron in its center 
(34). Hemoglobin can be degraded to heme (Fe2+) or the oxidized form hemin (Fe3+) 
by macrophages in liver, bone marrow and spleen (35). As shown in Fig. 5A and B, 
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hemoglobin, and even more methemoglobin, affected the membrane integrity, but did 
not decrease the ATP content of HL60 cells. The addition of MAA did not lead to a 
significant increase in the observed membrane toxicity or a decrease in the cellular 
ATP content. These findings were confirmed by the staining for apoptotic and 
necrotic cells, where only methemoglobin showed a significant higher percentage of 
apoptotic (but not necrotic) cells than control incubations (Fig. 5C). The addition of 
MAA did not significantly increase the percentage of apoptotic or necrotic cells in the 
presence of hemoglobin or methemoglobin. 
Since hemoglobin and methemoglobin represent large molecules wherein the iron 
ions are embedded, it is uncertain whether MAA was able to get in contact with the 
iron ions. We therefore also assessed the cytotoxicity of hemin, an early breakdown 
product of hemoglobin. Hemin consists of Fe3+ within a protoporphyrin ring but, in 
contrast to hemoglobin, without the globin chains (36). The iron is therefore probably 
more accessible for external molecules. As shown in Fig. 5D, hemin alone affected 
membrane integrity and this toxicity was significantly increased by MAA. Similarly, 
hemin alone reduced the ATP content of HL60 cells and this effect was accentuated 
in the presence of MAA (Fig. 5E). These results were confirmed by staining for 
apoptotic and necrotic cells, where the percentage of apoptotic cells was significantly 
increased by MAA and hemin compared to hemin alone (Fig. 5F). In order to confirm 
these results, we determined the activity of the pro-apoptotic caspases 3 and 7. After 
24 hours of incubation, the combination of hemin and MAA significantly increased the 
activity of caspase 3 in comparison to MAA or hemin alone (Fig. 6A), confirming the 
results shown in Fig. 5E. 
Interestingly, freshly isolated neutrophils were much more resistant to the toxic 
effects of hemin and MAA (Fig. 6B and 6C). The hemin concentration (12.5 µM) that 
induced membrane toxicity in HL60 cells was not cytotoxic and depleted the cellular 
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ATP pool only slightly. Furthermore, the addition of MAA did not increase plasma 
membrane toxicity or cellular ATP depletion in the presence of hemin. In contrary, 
MAA attenuated the drop in ATP in presence of 12.5 µM hemin. 
 
3.6. Effect of EDTA on plasma membrane toxicity of MAA in HL60 cells 
The next step was to expose HL60 cells to EDTA in order to chelate iron. In 
incubations containing MAA and hemin, EDTA reduced the plasma membrane 
toxicity of MAA and hemin to almost control levels. EDTA also attenuated the ATP 
depletion associated with MAA and hemin. These findings confirmed the important 
role of iron in the toxicity of hemin and MAA (data not shown). 
 
3.7. Prevention of the plasma membrane toxicity of MAA with antioxidants 
A possible explanation of the toxicity of MAA associated with hemin is the formation 
of reactive metabolites (radicals) from MAA (22). We investigated this possibility by 
the addition of antioxidants to the incubations, which can trap electrophilic reactive 
metabolites such as radicals. As shown in Fig. 7A and 7B, the addition of NAC 
efficiently prevented plasma membrane toxicity and ATP depletion associated with 
hemin or the combination of hemin and MAA, suggesting that the formation of 
reactive intermediates was responsible for the observed toxicity. As shown in Fig. 7C, 
NAC also increased the percentage of viable and reduced the percentage of 
apoptotic cells when co-incubated with hemin or the combination hemin and MAA 
compared to the respective incubations without NAC. As shown in Fig. 7D and 7E, 
glutathione also reduced membrane toxicity and ATP depletion when co-incubated 
with hemin or the combination hemin and MAA compared to the respective 
incubations without glutathione. 
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These results confirm the iron-associated formation of reactive metabolites as a 
mechanism for the toxicity of MAA on HL60 cells. 
 
3.8. Spectrophotometric monitoring of the interaction of MAA with hemin 
It is known that MAA interacts with Fe3+ ions in aqueous solution through an electron 
exchange that reduces Fe3+ to Fe2+. The reaction of MAA with FeCl3 has been used 
as an analytical method to detect the presence of MAA. The amount of analyte has 
been assessed from both absorption of the Fe2+-(MAA) complex (37) and of 
[Fe(phen)3]
2+ after reduction of Fe3+ to Fe2+ by MAA (38). 
Once iron is coordinated by a rigid square-planar ligand such as hemin, it is not 
available to form a complex with either MAA or 1,10-phenanthroline. If Fe3+ is 
reduced to Fe2+ in hemin by MAA, the reduction process should result in different 
spectroscopic properties of the porphyrin core. Keeping this in mind, we performed a 
spectrophotometric titration to assess the effect of MAA on hemin absorption. As 
shown in Fig. 8A, the addition of small amounts of MAA resulted in a decrease and 
redshift of the hemin absorption bands. In the region between 450 and 650 nm two 
bands remained, a spectroscopic signal of a metallated porphyrin core. In 
comparison, the spectrum of non-metallated protoporphyrin contains four bands in 
this region (39, 40)(38, 39)(37, 38). 
The absorption spectrum indicated that the electronic properties of the hemin ring 
were changing, possibly due to a change in the oxidation state of the aromatic ring or 
of the coordinated metal centre. 
 
3.9. Product identification by NMR 
After having confirmed an interaction between MAA and hemin, we moved on to the 
identification of the product resulting from this reaction. NMR spectroscopy was the 
  
19 
 
analytical method of choice, since it allows structural elucidation at both the proton 
and carbon level. We therefore incubated MAA and hemin in D2O at 37 °C for 192 
hours. From 1H NMR spectra obtained at different time points, it is evident that MAA 
converted to a single reaction product in less than 95 hours under our experimental 
conditions (Fig. 8B). The product did not undergo further transformations when 
incubated under these conditions for another four days. 
Figures 8C and 8D show a comparison of the 1H and 13C NMR spectra of the starting 
material MAA, the demethylated derivative AA and the reaction product detected 
under our experimental conditions. The signals have been assigned through 2D NMR 
experiments (COSY, NOESY, HMBC and HMQC) (Fig. 9A-C). The spectra show that 
the reaction product was not AA and allowed us to propose a possible structure of 
the reaction product (Fig. 8C). 
A possible reaction sequence leading to the proposed product is given in Fig. 9E. 
Finally, we simulated the 13C-NMR spectrum of the proposed product using the 
ChemBioDraw Ultra 14.0 software, which yielded a good match with the experimental 
spectrum (Fig. 9D). 
 
 
4. Discussion 
The current study shows that MAA, AA, FAA and AAA alone were not toxic for HL60 
cells, that MAA did not significantly increase the toxicity of Fe2+, Fe3+, hemoglobin or 
lactoferrin and that MAA increased the toxicity of H2O2 only at high concentrations 
(100 µM). On the other hand, MAA reduced Fe3+ to Fe2+ in hemin by a reaction 
producing reactive intermediates which may explain the increased cytotoxicity of 
hemin by MAA. 
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After having shown that MAA, AA, AAA and FAA are not toxic on HL60 cells and 
freshly isolated granulocytes up to 200 µM, we investigated the possibility that active 
and possibly cytotoxic metabolites could be formed via substrates and/or products of 
the myeloperoxidase reaction. Utrecht et al. have shown previously that toxic 
products can be formed from aminopyrine (dimethylaminoantipyrine) by hypochlorite, 
which is a reaction product of MPO (13). We therefore tested the effect of MAA on 
HL60 cells and granulocytes at different H2O2 concentrations. At low H2O2 
concentrations (<50 μM), MAA was protective for membrane toxicity and ATP 
depletion by H2O2, and only at the highest H2O2 concentration tested (100 µM), we 
observed an increased cytotoxicity associated with MAA. In plasma, H2O2 
concentrations are dependent on race and gender and vary between 1 to 5 µM (41, 
42). In patients with inflammatory diseases, the H2O2 concentration in plasma can 
reach 50 µM and up to 100 µM in activated phagocytes (42, 43). We could therefore 
not completely exclude the possibility that MAA in combination with high H2O2 
concentrations could become cytotoxic for cells in bone marrow. On the other hand, 
taking also into account the lack of toxicity on HL60 cells for the combination 100 µM 
hypochlorite and MAA, led us to the conclusion that substrates and/or reaction 
products of MPO are an unlikely cause for MAA-associated myelotoxicity. 
Next, we studied the possibility that the Fenton reaction could play a role in MAA-
associated myelotoxicity. The Fenton reaction describes the oxidation of organic 
substrates in the presence of iron salts and H2O2 (22). It has recently been described 
by Giri and Golder that metamizole can be degraded by a Fenton reaction (44). 
Although Giri and Golder used different conditions compared to the current study, 
e.g. a cell-free system, high H2O2 concentrations (22.5 mM) and an acid milieu (50 
mM H2SO4), they demonstrated that metamizole can be degraded in the presence of 
Fe2+ and H2O2 via several steps eventually leading to the production of hydroxyl 
  
21 
 
radicals. In the current study, aqueous Fe2+ and Fe3+ were not cytotoxic for HL60 
cells, irrespective of the absence or presence of MAA. In addition, Fe2+ did not 
increase the toxicity of H2O2, and, similar to incubations containing only H2O2, MAA 
was protective in the presence of Fe2+ and H2O2 combinations at H2O2 
concentrations <100 µM. These results suggested that the Fenton reaction played no 
important role in the myelotoxicity of MAA. Pierre et al. have described a change in 
the absorption spectrum of MAA in the presence of Fe2+ (or Fe3+) and H2O2, 
suggesting that MAA can react with Fe2+ (or an intermediate of the Fenton reaction) 
under these conditions (24). However, in the study of Pierre et al., the change in the 
absorption spectrum of MAA in the presence of Fe2+ and H2O2 was much smaller 
than the change observed in the presence complexed iron such as hemin. Taking 
into account the study of Pierre et al. (24) and the results of the current study we can 
conclude that MAA can be involved in Fenton reactions, but that such reactions are 
not associated in toxicity on HL60 cells. We therefore also excluded Fenton reactions 
as a likely possibility of cytotoxicity associated with MAA. 
As shown by Pierre et al. (24), MAA and AA (but not FAA and AAA) can react with 
complexed iron. We therefore studied possible interactions of MAA with lactoferrin, 
hemoglobin and methemoglobin. Lactoferrin is a serin protease containing Fe3+ 
which is expressed in promyelocytes during the development of neutrophil 
granulocytes (31, 32). It is stored in secondary granules of neutrophils and released 
on the granulocyte surface and into the blood during infections. In the current study, 
lactoferrin but not apo- or holo-lactoferrin was slightly membrane-toxic on HL60 cells, 
but this toxicity was not increased by MAA. We therefore excluded the possibility that 
cytotoxicity of MAA was associated with lactoferrin. Similarly, hemoglobin and 
methemoglobin were slightly membrane-toxic on HL60 cells, but did not decrease the 
cellular ATP content. Sine MAA did not increase the toxicity of hemoglobin and 
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methemoglobin; we excluded also possibility that hemoglobin or methemoglobin were 
associated with cytotoxicity of MAA. 
Next, we studied a possible interaction with hemin. Hemin is the degradation product 
of hemoglobin and contains Fe3+ in a porphyrin ring (45). Hemin can be taken up by 
cells and can react with H2O2 to produce cytotoxic radicals. Hemin itself was 
membrane-toxic and decreased the ATP content of HL60 cells and this toxicity was 
significantly increased by the addition of MAA. Further experiments showed that the 
toxicity of hemin and the combination hemin and MAA could almost completely be 
prevented by EDTA and by antioxidants such as NAC and glutathione. These 
findings indicated that Fe3+ and radical formation plaid a role in the toxicity of hemin 
and of the combination hemin and MAA. In spectrophotometric experiments, we 
could confirm an interaction between MAA and hemin. NMR studies allowed us then 
to identify a final reaction product and, based on the publication by Giri and Golder 
(44), to propose a reaction sequence leading to the stable reaction product. This 
sequence starts with N-demethylation and yields a reactive electrophilic intermediate 
that may be responsible for the cytotoxicity of the combination MAA and hemin. The 
formation of an electrophilic intermediate is in agreement with the finding in the 
current study that the antioxidants (or electron donors) NAC and glutathione were 
able to prevent the toxicity of MAA and hemin.  
The current study suggests that the availability of hemin, e.g. after bleeding or after 
hemolysis represents a risk factor for MAA-associated myelotoxicity. In the study of 
Blaser et al. (7), patients with pre-existing hypersensitivity reactions, concomitant 
drugs known to be associated with leukopenia, hepatitis C infection and pre-existing 
hematological diseases were overrepresented in patients with metamizole-associated 
leukopenia compared to control persons, but only a minority of the patients was 
carrier of such factors. While immunological factors may trigger metamizole-
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associated granulocytopenia in some patients, non-immunological factors may trigger 
this adverse reaction in others. Increased breakdown of erythrocytes with abundant 
hemin may be one of them. 
In conclusion, MAA, the principle metabolite of metamizole, clearly increased the 
cytotoxicity of hemin by a reaction involving the formation of an electrophilic 
metabolite. Toxicity could be prevented by electron donors such as NAC and 
glutathione. Situations with increased production of hemin such as extravascular 
hemolysis may be a risk factor for metamizole-associated granulocytopenia. 
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Legends to Figures 
Figure 1 
Metabolism of metamizole. Metamizole is rapidly converted non-enzymatically in the 
intestinal tract to the active metabolite N-methyl-4-aminoantipyrine (MAA). MAA has 
a good oral bioavailability and can be converted enzymatically to the 4-
aminoantipyrine (AA) or formylated to N-formyl-4-aminoantipyrine (FAA). The 
majority of AA is acetylated to N-acetyl-4-aminoantipyrine (AAA). 
 
Figure 2 
Effect of N-methyl-4-aminoantipyrine (MAA), 4-aminoantipyrine (AA), N-formyl-4-
aminoantipyrine (FAA) and N-acetyl-4-aminoantipyrine (AAA) on cytotoxicity for HL60 
cells and freshly isolated neutrophil granulocytes. Cells were treated with the 
toxicants for 24 hours. Membrane integrity was determined as the release of 
adenylate kinase into the supernatant of HL60 cells (A) and neutrophil granulocytes 
(C). The cellular ATP content was determined in HL60 cells (B) and neutrophil 
granulocytes (D). There were no statistically significant differences between 
treatments and controls in HL60 cells or neutrophil granulocytes. Ctrl: control, Tx: 
0.1% Triton X. 
 
Figure 3 
Effect of H2O2 and MAA on HL60 cells. Cells were treated with different H2O2 
concentrations in the absence or presence of 100 µM MAA for 24 hours. (A) Effect 
on adenylate kinase release (marker of membrane integrity), (B) effect on 
intracellular ATP concentration and (C) effect on cell death by apoptosis or necrosis. 
Apoptosis and necrosis were assessed by staining with Annexin V and propidium 
iodide, respectively. *p<0.05 vs. control incubations (Ctrl), +p<0.05 vs. incubations 
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w/o MAA of the same treatment group. Ctrl: control, Tx: 0.1% Triton X, MAA: N-
methyl-4-aminoantipyrine. 
 
Figure 4 
Effect of FeSO4, H2O2, lactoferrin and MAA on HL60 cells. Cells were treated with 
FeSO4 (12.5 µM) and different H2O2 concentrations in the absence or presence of 
100 µM MAA for 24 hours. Apoptosis and necrosis were assessed by staining with 
Annexin V and propidium iodide, respectively. (A) Effect of FeSO4 (12.5 µM) and 
H2O2 on adenylate kinase release (marker of membrane integrity), (B) effect of 
FeSO4 (12.5 µM) and H2O2 on intracellular ATP concentration and (C) effect on cell 
death by apoptosis or necrosis. Apo-lactoferrin and holo-lactoferrin were prepared as 
described in Methods. Cells were treated with the different lactoferrins in the 
presence or the absence of MAA for 24 hours. (D) Effect of lactoferrin on adenylate 
kinase release (marker of membrane integrity), (E) effect of lactoferrin on intracellular 
ATP concentration. *p<0.05 vs. control incubations (Ctrl).  *p<0.05 vs. control 
incubations (Ctrl), +p<0.05 vs. incubations w/o MAA of the same treatment group. 
Ctrl: control, Tx: 0.1% Triton X, MAA: N-methyl-4-aminoantipyrine. 
 
Figure 5 
Effect of hemoglobin, methemoglobin, hemin and MAA on HL60 cells. Cells were 
treated with hemoglobin, methemoglobin or hemin in the absence or presence of 100 
µM MAA for 24 hours. (A) Effect on adenylate kinase release (marker of membrane 
integrity) by hemoglobin and methemoglobin, (B) effect on intracellular ATP 
concentration by hemoglobin and methemoglobin and (C) effect on cell death by 
apoptosis or necrosis by hemoglobin and methemoglobin. (D) Effect on adenylate 
kinase release (marker of membrane integrity) by hemin, (E) effect on intracellular 
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ATP concentration by hemin and (F) effect on cell death by apoptosis or necrosis by 
hemin. Apoptosis and necrosis were assessed by staining with Annexin V and 
propidium iodide, respectively. *p<0.05 vs. control incubations (Ctrl), +p<0.05 vs. 
incubations w/o MAA of the same treatment group. Ctrl: control, Tx: 0.1% Triton X, 
MAA: N-methyl-4-aminoantipyrine. 
 
Figure 6 
Effect of hemin and MAA on caspase 3 activity in HL60 cells as well as effect on cytotoxicity 
in neutrophil granulocytes. (A) HL60 cells were treated with 12.5 µM hemin in the absence or 
presence of 100 µM MAA for 24 hours. Caspase 3 activity was measured using 
luminescence as described in Methods. Doxorubicin was used as a positive control.  
(B-C) Freshly isolated neutrophil granulocytes were treated with 12.5 or 25 µM hemin in the 
absence or presence of 100 µM MAA for 24 hours. (B) Effect on adenylate kinase release 
(marker of membrane integrity), (C) effect on intracellular ATP concentration. *p<0.05 vs. 
control incubations (Ctrl), Ctrl: control, Tx: 0.1% Triton X, MAA: N-methyl-4-aminoantipyrine. 
 
 
Figure 7 
Effect of N-acetylcysteine (NAC), glutathione (GSH), and MAA on the effect of hemin 
on HL60 cells. Cells were treated with hemin in absence or presence of NAC or MAA 
for 24 hours. (A) Effect on adenylate kinase release (marker of membrane integrity), 
(B) effect on intracellular ATP concentration and (C) effect on cell death by apoptosis 
or necrosis. Apoptosis and necrosis were assessed by staining with Annexin V and 
propidium iodide, respectively. Cells were treated with hemin in absence or presence 
of GSH or MAA for 24 hours.  (D) Effect on adenylate kinase release (marker of 
membrane integrity), (E) effect on intracellular ATP concentration.  *p<0.05 vs. 
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control incubations (Ctrl), +p<0.05 vs. incubations w/o NAC or GSH of the same 
treatment group. Ctrl: control, Tx: 0.1% Triton X, MAA: N-methyl-4-aminoantipyrine. 
 
Figure 8 
Reaction of MAA with hemin. (A) Hemin was dissolved in D2O and an absorption 
spectrum was recorded in the range of 200 to 700 nm. MAA was added to the 
solution in steps of 0.5 equivalents up to 4 equivalents. The blue line represents the 
spectrum of MAA alone and the red line hemin in the presence of 4 equivalents MAA. 
(B) Hemin was dissolved in D2O and 4 equivalents of MAA added. The solution was 
kept at 37 °C and 1H and 13C NMR spectra were recorded at room temperature at 
the time points indicated. (C) Comparison of the 1H NMR spectra obtained from the 
starting material MAA, the demethylated derivative AA and the proposed reaction 
product (D) Comparison of the 13C NMR spectra obtained from the starting material 
MAA, the demethylated derivative AA and the proposed reaction product. MAA: N-
methyl-4-aminoantipyrine, AA: 4-aminoantipyrine. The title of the ordinates in Fig. B, 
C and D is intensity without units. 
 
Figure 9 
Reaction pathway and comparison of the reaction product with simulated 13C-NMR 
spectrum. (A) 500 MHz NOESY spectrum of a D2O solution of the reaction product 
(295 K). δ = 4.79 ppm residual solvent peak. (B) HMQC spectrum (1H, 500 MHz; 13C, 
126 MHz) of a D2O solution of the reaction product (295 K). δ = 4.79 ppm residual 
solvent peak. Hydrogen-bearing carbons are assigned. (C) HMBC spectrum (1H, 500 
MHz; 13C, 126 MHz) of a D2O solution of the reaction product (295 K). δ = 4.79 ppm 
residual solvent peak. Quaternary carbons are assigned. (D) The simulated 13C-NMR 
spectrum of the proposed product (using ChemBioDraw Ultra 14.0 software) yielded 
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a good match with the real spectrum. (E) The proposed reaction pathway is based on 
the publication by Giri and Golder (44). This pathway includes an electrophilic 
intermediate, which may be trapped by electron donors such as NAC and glutathione 
and which may be cytotoxic. MAA: N-methyl-4-aminoantipyrine, A: antipyrine, 4,5-
OH-A: 4,5-dihydroxyantipyrine. 
 
  
  
33 
 
Graphical abstract 
 
